Opening Microenvironmental Determinants of Systemic Therapy Response in Kidney Cancer
Microenvironmental Determinants of Systemic Therapy Response in Kidney Cancer
- Length
- 56 min
- Level
- Research
- Recorded
- Yale University2024
Chapter 1 of 9: Before the lecture
Hakimi ties tumor-associated macrophages, not mutational burden, to immunotherapy resistance in kidney cancer.
Kidney cancer response to systemic therapy depends heavily on the tumor microenvironment and myeloid cell infiltration. The talk analyzes clear cell renal cell carcinoma through both human patient samples and murine models to bridge genomic findings with clinical outcomes. Bulk and single-cell RNA sequencing reveal that tumor-associated macrophages drive treatment resistance and metastatic recurrence independently of mutational burden. Mouse models validate these transcriptional signatures and demonstrate that targeting myeloid phenotypes can alter therapeutic response. The findings ultimately offer a framework for refining patient risk stratification and optimizing combinatorial immunotherapy trials.
Kidney cancer response to systemic therapy depends heavily on the tumor microenvironment and myeloid cell infiltration. The talk analyzes clear cell renal cell carcinoma through both human patient samples and murine models to bridge genomic findings with clinical outcomes. Bulk and single-cell RNA sequencing reveal that tumor-associated macrophages drive treatment resistance and metastatic recurrence independently of mutational burden. Mouse models validate these transcriptional signatures and demonstrate that targeting myeloid phenotypes can alter therapeutic response. The findings ultimately offer a framework for refining patient risk stratification and optimizing combinatorial immunotherapy trials.
Comprehensive molecular characterization of clear cell renal cell carcinoma
TRACERx Renal
Evolutionary subtypes study
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
Immotion150
BMS Niro trials
BMS 214

This lecture
Talk 18 of 26 of Yale Cancer Center Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
Javelin 101
Ricketts et al Study
Rooney et al Study
Senbabagilu et al Study
Senbabaoğlu...Hakimi Genome Bio 2016
McDermott et al. Nat medicine 2018
Hakimi et al Canc Discovery 2019
Motzer et al Nat Med 2020
Krishna....Hakimi Cancer Cell 2021
Cancer Cell 2021
New England Journal paper on intratumoral heterogeneity
Paper on advanced disease and EVIVO treated
Braun et al Cancer Cell 2021
Rappold et al Cancer Discovery 2022
Cancer Cell publication by Krishna et al.
Cancer Discovery publication by Rappold et al.
Nature Medicine publication by Frew et al.
PyzPech Nat Med 2013
Novartis